Free Trial

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com

Syros Pharmaceuticals logo with Medical background

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Monday.

Several other research firms also recently weighed in on SYRS. HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Syros Pharmaceuticals in a research report on Friday. JMP Securities lowered their target price on Syros Pharmaceuticals from $12.00 to $4.00 and set a "market outperform" rating on the stock in a research report on Tuesday, August 13th. Finally, Piper Sandler restated an "overweight" rating and issued a $5.00 price target (down previously from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th.

Check Out Our Latest Stock Analysis on SYRS

Syros Pharmaceuticals Stock Performance

Shares of SYRS stock traded up $0.17 on Monday, reaching $2.43. The stock had a trading volume of 398,776 shares, compared to its average volume of 243,605. The stock has a market cap of $65.15 million, a P/E ratio of -0.80 and a beta of 1.59. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.46 and a current ratio of 3.46. Syros Pharmaceuticals has a 1 year low of $1.43 and a 1 year high of $8.17. The company has a 50 day simple moving average of $1.94 and a 200 day simple moving average of $3.94.

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the firm earned ($1.35) earnings per share. Equities research analysts expect that Syros Pharmaceuticals will post -3.06 EPS for the current year.

Insider Transactions at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, CFO Jason Haas purchased 35,363 shares of the firm's stock in a transaction on Tuesday, September 10th. The shares were acquired at an average cost of $1.55 per share, with a total value of $54,812.65. Following the completion of the acquisition, the chief financial officer now directly owns 59,915 shares in the company, valued at $92,868.25. The trade was a 100.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Conley Chee bought 50,000 shares of the company's stock in a transaction that occurred on Tuesday, September 10th. The stock was purchased at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the transaction, the chief executive officer now owns 72,504 shares in the company, valued at $109,481.04. The trade was a 200.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Jason Haas bought 35,363 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The shares were bought at an average cost of $1.55 per share, with a total value of $54,812.65. Following the completion of the purchase, the chief financial officer now directly owns 59,915 shares of the company's stock, valued at $92,868.25. This represents a 100.00 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 130,707 shares of company stock valued at $206,491 over the last three months. Corporate insiders own 12.26% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Certuity LLC purchased a new stake in shares of Syros Pharmaceuticals in the second quarter worth about $109,000. Acadian Asset Management LLC raised its holdings in shares of Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company's stock worth $178,000 after acquiring an additional 17,416 shares in the last quarter. Opaleye Management Inc. boosted its position in shares of Syros Pharmaceuticals by 119.1% during the 1st quarter. Opaleye Management Inc. now owns 787,545 shares of the company's stock valued at $4,213,000 after acquiring an additional 428,175 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Syros Pharmaceuticals in the first quarter valued at $64,000. Finally, Kennedy Capital Management LLC purchased a new position in shares of Syros Pharmaceuticals in the first quarter valued at $2,166,000. Institutional investors own 91.47% of the company's stock.

Syros Pharmaceuticals Company Profile

(Get Free Report)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Trump won. Buy this coin now. (From Weiss Ratings) (Ad)

Should you invest $1,000 in Syros Pharmaceuticals right now?

Before you consider Syros Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syros Pharmaceuticals wasn't on the list.

While Syros Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?
These Top Stocks in 2024 Will Continue to be Big Winners in 2025
’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines